Wegovy vs Saxenda: Cost and Access Head-to-Head

How Wegovy and Saxenda Work: The Same Target, Different Molecules

Both drugs activate the glucagon-like peptide-1 (GLP-1) receptor, which slows gastric emptying, suppresses appetite in the hypothalamus, and modulates insulin secretion. The mechanism is shared, but the molecules are structurally different and that difference drives meaningful gaps in potency, dosing frequency, and clinical outcomes.

Semaglutide vs Liraglutide: Structural Differences That Matter

Semaglutide has an albumin-binding fatty-acid chain that extends its half-life to approximately 165 hours, enabling once-weekly dosing. Liraglutide has a shorter fatty-acid attachment, yielding a half-life of roughly 13 hours and requiring once-daily injections. FDA prescribing information for Wegovy confirms a subcutaneous bioavailability of approximately 89%.

A longer half-life does more than simplify the injection schedule. Steadier plasma concentrations may reduce peak-to-trough side-effect fluctuations, though head-to-head pharmacokinetic data in the same patient population are not available.

Receptor Affinity and Downstream Potency

Semaglutide binds the GLP-1 receptor with roughly three times the affinity of liraglutide in vitro. That higher receptor occupancy likely explains much of the efficacy gap seen in clinical trials, though direct mechanistic comparisons in humans are limited. Both drugs are agonists at the same receptor; the difference is degree, not kind.

Efficacy: What the Phase-3 Trials Show

No direct head-to-head randomized trial has pitted Wegovy against Saxenda. All efficacy comparisons draw on separate phase-3 programs with different trial designs, populations, and durations. Cross-trial comparisons should be interpreted with caution.

STEP-1: The Wegovy Evidence Base

STEP-1 (N=1,961) enrolled adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity, and no type 2 diabetes. Participants received semaglutide 2.4 mg subcutaneously once weekly or placebo for 68 weeks alongside lifestyle intervention. Mean body-weight loss was 14.9% in the semaglutide group versus 2.4% in the placebo group (P<0.001). Wilding JPH et al., NEJM 2021.

Beyond mean weight loss, 86.4% of semaglutide participants lost at least 5% of body weight, versus 31.5% on placebo. More than a third (38.5%) of those on semaglutide lost 20% or more of body weight.

SCALE Obesity and Prediabetes: The Saxenda Evidence Base

SCALE Obesity and Prediabetes (N=3,731) tested liraglutide 3 mg once daily versus placebo for 56 weeks in adults with a BMI of 30 or higher, or 27 or higher with dyslipidemia or hypertension. Mean weight loss was 8.0% with liraglutide versus 2.6% with placebo (P<0.001). Pi-Sunyer X et al., NEJM 2015.

Sixty-three percent of liraglutide participants lost at least 5% of body weight, compared with 27% on placebo.

Interpreting the Gap

The approximate 7-percentage-point difference in mean weight loss (14.9% vs 8.0%) is substantial in clinical terms. For a 250-pound (113 kg) person, that translates to roughly 37 pounds (17 kg) lost with semaglutide versus 20 pounds (9 kg) with liraglutide. The trials used different durations (68 weeks vs 56 weeks) and slightly different enrollment criteria, which limits direct comparison. Still, the gap is large enough that most obesity-medicine specialists consider semaglutide the more effective agent when both are accessible.

Dosing and Administration

Wegovy Titration Schedule

Wegovy starts at 0.25 mg once weekly for 4 weeks, then increases every 4 weeks through 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg. The full titration takes 16 weeks. Each dose comes in a single-use auto-injector pen; one carton contains four pens (a 28-day supply at the maintenance dose).

Saxenda Titration Schedule

Saxenda starts at 0.6 mg once daily for one week and increases by 0.6 mg each week until the 3.0 mg maintenance dose is reached over five weeks. Each prefilled pen delivers 6 mg per mL and contains 18 mg total, lasting approximately six days at the 3.0 mg dose. Patients therefore go through roughly five pens per 30-day supply.

Injection Technique and Storage

Both drugs are injected subcutaneously into the abdomen, thigh, or upper arm. Both require refrigeration (36°F to 46°F / 2°C to 8°C) until first use; after first use, Saxenda pens can be stored at room temperature (up to 77°F / 25°C) for up to 30 days. Wegovy pens should be kept refrigerated but may be stored at room temperature for up to 28 days if needed.

Side-Effect Profiles

Shared GLP-1 Class Effects

Nausea, vomiting, diarrhea, and constipation are the most common adverse effects for both drugs. These typically peak during dose escalation and diminish at steady state. In STEP-1, nausea occurred in 44% of the semaglutide group versus 16% in the placebo group. In SCALE, nausea affected 39.3% of the liraglutide group versus 14.5% on placebo.

Serious Risks: Shared Class Warnings

Both drugs carry an FDA boxed warning for thyroid C-cell tumors based on rodent studies. Neither drug is recommended in patients with a personal or family history of medullary thyroid carcinoma or in those with Multiple Endocrine Neoplasia syndrome type 2. Acute pancreatitis has been reported with both agents, and both should be discontinued if pancreatitis is confirmed.

Injection-Site Reactions and Pen Handling

Daily injections with Saxenda create more frequent opportunities for injection-site reactions (erythema, nodules, bruising). Wegovy's once-weekly regimen reduces that exposure by a factor of seven. Patients who report injection fatigue or site reactions on Saxenda may find the weekly schedule more tolerable, though individual responses vary.

Cost: List Price, Insurance, and Out-of-Pocket Reality

List Price in the US (2024)

The retail list price for both Wegovy and Saxenda is in the range of $1,300 to $1,350 per month in the United States as of mid-2024, which places them among the most expensive outpatient medications in primary care. The near-identical list prices are somewhat misleading because the drugs deliver meaningfully different efficacy and dosing frequency.

Novo Nordisk manufactures both drugs. The company has acknowledged in SEC filings that US net prices (after rebates) are significantly lower than list prices, but those negotiated rates are not publicly disclosed per product.

Commercial Insurance Coverage

Coverage varies widely by plan. As of 2024, the majority of commercial insurance plans cover Saxenda for obesity when specific criteria are met (BMI of 30 or higher, or 27 or higher with a comorbidity, plus documented diet and exercise failure). Wegovy coverage has expanded since its June 2021 approval, but a significant proportion of large employer-sponsored plans still exclude it or apply prior-authorization requirements that Saxenda does not face.

The American Society of Metabolic and Bariatric Surgery and the Obesity Society have both published position statements urging payers to cover anti-obesity medications, noting that the 2013 American Medical Association classification of obesity as a disease should obligate coverage parity with other chronic disease treatments.

Medicare and Medicaid

Medicare Part D historically excluded drugs approved exclusively for weight loss under the exclusion codified in Section 1927 of the Social Security Act. The Treat and Reduce Obesity Act (TROA), reintroduced multiple times in Congress, would change that exclusion, but as of mid-2024 it has not passed. Saxenda and Wegovy are both affected equally by this exclusion unless the patient has a covered comorbidity (type 2 diabetes for Wegovy only, given Ozempic's approval pathway).

Medicaid coverage is state-by-state. Approximately 25 states cover at least one GLP-1 agonist for obesity management as of 2024, according to the Obesity Action Coalition's coverage map.

Manufacturer Savings Programs

Novo Nordisk offers a savings card for Wegovy that brings the monthly co-pay to as low as $0 for eligible commercially insured patients (income and insurance eligibility criteria apply; program subject to change). A similar savings card for Saxenda is available, also potentially reducing co-pay to $25 per month for eligible patients.

Uninsured patients pay list price unless they qualify for Novo Nordisk's patient assistance program (NovoCare), which provides medication at no cost to patients meeting income thresholds (generally at or below 400% of the federal poverty level).

Compounded Semaglutide: A Cost Note

Compounded semaglutide (not FDA-approved Wegovy) became widely available through 503A and 503B compounding pharmacies during the Wegovy shortage period. Prices range from $200 to $400 per month. The FDA has not approved compounded semaglutide for any indication, and the FDA has issued guidance flagging safety concerns with compounded GLP-1 products. No compounded liraglutide equivalent is in broad circulation.

Access and Availability

Supply Chain History

Wegovy faced significant supply shortages from mid-2022 through most of 2023 following unexpectedly high demand after its 2021 launch. Novo Nordisk prioritized certain dose strengths, leaving patients mid-titration stranded at sub-therapeutic doses. Saxenda did not face equivalent supply disruptions during the same period, making it a practical fallback for some patients and prescribers.

As of mid-2024, Novo Nordisk reports that all Wegovy dose strengths are available, though regional shortfalls can still occur.

Telehealth Prescribing

Both Wegovy and Saxenda are Schedule V or unscheduled medications (they are not controlled substances), which means telehealth prescribing does not face the same federal restrictions that apply to Schedule III and IV drugs. Both can be prescribed via synchronous or asynchronous telehealth visits in most states, making telehealth platforms a meaningful access point for patients in rural or underserved areas.

International Access

Outside the US, pricing and availability differ substantially. In the UK, NHS England began a phased rollout of Wegovy in 2023 through specialist weight management services, with access limited to those with a BMI of 35 or higher and at least one comorbidity. Saxenda has been available on the NHS in England (through specialist services) and privately since 2017. In Canada, Wegovy received Health Canada approval in November 2021, and Saxenda has been available since 2015.

Which Drug Is Right for Which Patient?

The choice between Wegovy and Saxenda is not purely pharmacological. Clinical context, insurance status, supply availability, and patient preference each shape the decision. The framework below organizes the key decision points.

When Wegovy Is the Preferred Choice

Wegovy is the preferred agent when:

• The patient has commercial insurance that covers it (or qualifies for the $0 savings card).
• The treatment goal requires at least 10% to 15% body-weight loss to achieve metabolic benefit (for example, to reverse prediabetes or achieve surgical eligibility criteria).
• The patient has already trialed Saxenda and achieved less than 5% weight loss at the 3 mg dose after 12 weeks, a threshold recommended by the SCALE trial authors for evaluating non-response.
• The patient reports injection fatigue or adherence difficulty with daily injections.

When Saxenda May Be the Better Starting Point

Saxenda may be the more practical first choice when:

• Wegovy is not covered by insurance and the patient cannot afford the list price.
• There is a regional Wegovy supply shortage affecting the patient's dose strength.
• The prescriber wants a drug with a longer post-marketing safety record in a particular population (Saxenda has been on the market since 2014, providing nearly a decade of real-world pharmacovigilance data).
• The patient has a documented GLP-1 intolerance history and the prescriber wants finer-grained titration control. Saxenda's weekly 0.6 mg dose steps allow slower escalation than Wegovy's 4-week intervals, which may be useful for patients who are highly sensitive to GI side effects.

Patients Who Should Avoid Both

Neither drug should be used in pregnancy. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. Patients with a prior history of pancreatitis require careful risk-benefit discussion before initiating either agent.

Switching Between Wegovy and Saxenda

Switching is done in clinical practice, though the optimal transition protocol has not been evaluated in a randomized trial. The most common approach is to stop liraglutide and begin semaglutide titration at the lowest dose (0.25 mg weekly), with no mandatory washout given the absence of pharmacokinetic interactions. Some prescribers begin semaglutide the day after the last liraglutide injection.

Dr. Fatima Cody Stanford, an obesity medicine physician and researcher at Massachusetts General Hospital, has noted in published commentary that GLP-1 receptor agonist class effects mean patients switching from liraglutide to semaglutide may experience a recurrence of GI side effects during semaglutide titration, even if they had fully adapted to liraglutide. Patients should be counseled accordingly before switching.

Switching from Wegovy to Saxenda (downgrade for cost or supply reasons) is less common and may result in weight regain. A 2022 analysis of GLP-1 discontinuation published in Obesity showed that patients who stopped semaglutide regained approximately two-thirds of their lost weight within one year. Transitioning to a less potent agent rather than stopping entirely may blunt some regain, but no trial data specifically address this transition. Wilding JPH et al., Obesity 2022.

Cardiovascular Outcomes: What the Data Show

Wegovy: SELECT Trial Results

The SELECT trial (N=17,604) enrolled adults with established cardiovascular disease, BMI of 27 or higher, and no diabetes. Semaglutide 2.4 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 20% versus placebo over a mean follow-up of 33.3 months (HR 0.80, 95% CI 0.72 to 0.90, P<0.001). Lincoff AM et al., NEJM 2023. This result led the FDA to approve Wegovy for cardiovascular risk reduction in March 2024, making it the first anti-obesity medication with this indication.

Saxenda: LEADER Trial Context

Liraglutide 1.8 mg (Victoza, a lower dose than Saxenda) demonstrated cardiovascular benefit in the LEADER trial (N=9,340) in patients with type 2 diabetes. Liraglutide 3 mg (Saxenda) has not completed a dedicated cardiovascular outcomes trial for obesity without diabetes. That distinction matters for payers and prescribers when a patient's primary driver for treatment is cardiovascular risk reduction.

Summary Table: Wegovy vs Saxenda at a Glance

| Feature | Wegovy (semaglutide 2.4 mg) | Saxenda (liraglutide 3 mg) | |---|---|---| | Dosing frequency | Once weekly | Once daily | | Mean weight loss (phase 3) | 14.9% at 68 weeks | 8.0% at 56 weeks | | FDA approval year | 2021 | 2014 | | US list price (2024) | ~$1,349/month | ~$1,349/month | | CV outcomes trial (obesity) | SELECT (positive, 2023) | None completed | | Titration duration | 16 weeks | 5 weeks | | Supply history | Shortages 2022-2023 | Stable | | Compounded alternative available | Yes (unregulated) | No |